Nippon Steel exec says firm needs freedom to manage U.S. Steel, newspaper says
President Donald Trump walks with workers as he tours U.S. Steel Corporation's Mon Valley Works-Irvin plant, Friday, May 30, 2025, in West Mifflin, Pa. (AP Photo/Julia Demaree Nikhinson)
Shares of U.S. Steel dipped after a Nippon Steel executive told the Japanese Nikkei newspaper that its planned takeover of the company required 'a degree of management freedom' to go ahead, even as sources told Reuters a deal with the U.S. government to greenlight the tie-up was effectively done.
'Without a degree of management freedom, it may not be possible to reach an agreement with the U.S. government,' the executive said, according to the newspaper, sending shares of the iconic U.S. steelmaker down 4 per cent.
The comments appeared to take aim at remarks made by President Donald Trump, who said on Thursday that he had control over U.S. Steel via a 'golden share' that gave the American people a 51 per cent stake in the company.
But two of the three people said the deal could be finalized as soon as Friday.
Nippon Steel, U.S. Steel and the White House did not immediately respond to requests for comment.
The US$14.9 billion bid, first announced by Nippon Steel in December 2023, has faced opposition from the start. Both former President Joe Biden and Trump asserted last year that U.S. Steel should remain U.S.-owned, as they sought to woo voters ahead of the presidential election in Pennsylvania, where the company is headquartered.
Biden blocked the deal in January on national security grounds, prompting lawsuits by the companies, which argued the national security review they received was biased. The Biden White House disputed the charge.
The steel companies saw a new opportunity in the Trump administration, which began on January 20 and opened a fresh 45-day national security review into the proposed merger in April.
But Trump's public comments, ranging from welcoming a simple 'investment' in U.S. Steel by the Japanese firm to floating a minority stake for Nippon Steel, spurred confusion.
At a rally in Pennsylvania on May 30, Trump lauded an agreement between the companies and said Nippon Steel would make a 'great partner' for U.S. Steel. But he later told reporters the deal still lacked his final approval, leaving unresolved whether he would allow Nippon Steel to take ownership.
Nippon Steel and the Trump administration asked a U.S. appeals court on June 5 for an eight-day extension of a pause in litigation to give them more time to reach a deal for the Japanese firm. The pause expires Friday, but could be extended.
June 18 is the expiration date of the current acquisition contract between Nippon Steel and U.S. Steel, but the firms could agree to postpone that date.
---
Reporting by Alexandra Alper in Washington, David Gaffen in New York, and Nathan Gomes in Bengaluru; Editing by Anil D'Silva
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
39 minutes ago
- Globe and Mail
Viking Therapeutics Stock (VKTX): This Underrated Russell 2000 Gem Could Skyrocket 200%
Viking Therapeutics (VKTX) is quickly emerging as one of the most promising biotech stocks in the small-cap Russell 2000 index. With Wall Street analysts projecting a potential upside of over 200%, the stock has captured the attention of growth-focused investors. Backed by a strong pipeline targeting obesity and liver diseases, Viking's innovative therapies could pave the way for major breakthroughs and significant shareholder returns. Confident Investing Starts Here: VKTX's Bullish Case Viking Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies targeting metabolic and endocrine disorders. Their pipeline includes promising candidates for treating obesity, non-alcoholic fatty liver disease (NAFLD), and muscle wasting. Understandably, clinical-stage biotech firms come with high risk. Their treatments might never make it through trials or reach the market, and even if they do, profits aren't guaranteed. The company currently has no approved products, no revenue, and runs at a loss. During times of market uncertainty, investors often shy away from companies like this. However, Viking Therapeutics stands out from many other biotech firms. It's working on treatments for several major health issues, especially in areas where better options are needed. One key focus is weight loss, a market that's been growing fast and still has a lot of room to expand. Viking's top drug candidate, VK2735, targets both GLP-1 and GIP receptors, a combination found in Eli Lilly's (LLY) Zepbound, the current market leader and only approved drug of its kind so far. Additionally, the company is seeing encouraging results from its mid-stage program VK2809, aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). For context, MASH is a liver disease linked to obesity and becoming increasingly common. While the FDA only approved the first treatment for MASH last year, more approvals are expected shortly. Is Viking Therapeutics a Good Stock to Buy? Viking Therapeutics stock carries high risk, making it unsuitable for cautious investors. However, for those comfortable with volatility, a small position could offer strong long-term upside while limiting potential losses if the company fails. According to TipRanks, VKTX stock has received a Strong Buy consensus rating, with 13 Buys and one Hold assigned in the last three months. The average Viking Therapeutics stock price target is $90.7, suggesting a potential upside of nearly 217.32% from the current level. Year-to-date, VKTX stock has declined by almost 30%. See more VKTX analyst ratings
Globe and Mail
an hour ago
- Globe and Mail
Billionaire Bill Ackman Just Joined Warren Buffett and Cathie Wood by Adding This Monster Artificial Intelligence (AI) Stock to His Portfolio
Bill Ackman is a billionaire hedge fund manager as CEO of Pershing Square Capital Management. Unlike many of his peers on Wall Street, Ackman primarily keeps a tightly concentrated portfolio, with Pershing Square owning only about 10 stocks at any given time. For the last couple of years, Pershing Square's most direct artificial intelligence (AI) investment has been a sizable position in Alphabet. Ackman has made it clear that its diversified ecosystem -- spanning internet search, cloud computing, advertising, cybersecurity, and more -- combined with an attractive valuation is what enticed Pershing Square to take a position in the "Magnificent Seven" member. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Well, just a few weeks ago, news broke that Pershing Square had recently initiated a position in another AI stock, Amazon (NASDAQ: AMZN). Ackman now joins Warren Buffett, whom he is known to admire, and Cathie Wood as prominent personalities on Wall Street who have exposure to Amazon, through their respective portfolios at Berkshire Hathaway and ARK Invest. Let's explore what makes Amazon such a compelling AI stock for the long haul. I'll break down some trends in the business and the company's valuation to help explain why Amazon has earned the approval of Ackman, Buffett, and Wood. Amazon has a compelling AI narrative and... Given how hot AI has become, investors may be challenged to identify which opportunities are best suited for long-term positions. What I mean by that is while semiconductor stocks or AI software businesses have risen in popularity over the last couple of years, it's hard to know which of these companies will continue to be a market leader in 10 years (or longer). To me, Amazon is like the business version of a Swiss Army knife. The company's core segments are e-commerce and cloud computing infrastructure via Amazon Web Services (AWS). But it also has a thriving advertising business and a growing subscription service (Amazon Prime), and it has even made some progress in the streaming and entertainment landscape. Similar to Alphabet, Amazon is uniquely positioned to stitch its various operating units together through more AI-powered services. In essence, by leveraging the power of AI, it can bolster both the consumer and enterprise sides of its business and make the platform increasingly sticky for its customers. ... the company's investments are already bearing fruit While the ideas above sound great in theory, let's explore how the business has performed over the last couple of years since it started investing aggressively in AI. The first headline-grabbing move it made in AI was its investment in OpenAI rival Anthropic. The thesis around this partnership was to train Anthropic's generative AI model on AWS -- essentially integrating the efficiency of large language models into the AWS platform. Anthropic also agreed to use Amazon's in-house Trainium and Inferentia chipsets, providing the company with a direct avenue to begin scaling up a new part of its existing hardware business. Since Anthropic joined forces with Amazon, AWS revenue has accelerated considerably. But more important, operating income from Amazon's cloud business has almost doubled! AMZN Cash from Operations (TTM) data by YCharts; TTM = trailing 12 months. When you consider that Amazon's AI-driven growth is primarily sourced through just the cloud business right now, it becomes clearer that the company can leverage its robust profitability to reinvest in other areas of its business and jump-start those, too. I think that comes into focus as Wall Street's consensus revenue and earnings estimates over the next few years suggest there is much more growth ahead. AMZN Revenue Estimates for Current Fiscal Year, data by YCharts; EPS = earnings per share. Is Amazon a buy right now? Like many of its peers in the technology sector, Amazon has enjoyed a bit of a roller coaster ride so far this year. Shares bottomed at roughly $167 in April, which is likely when Ackman pounced. I say that because Pershing Square's position in Amazon was not included in the company's form 13F filing for the first quarter (ended March 31). If you had bought the dip in Amazon when Ackman did, you would have paid around 27 times forward earnings. AMZN PE Ratio (Forward) data by YCharts; PE = price to earnings. Among the 70 analysts who cover the stock, 66 rate it as either a buy or strong buy. Furthermore, with an average price target of $239, Wall Street's estimates imply there is still some modest upside. While Amazon's valuation has expanded over the last month and a half, the company's long-run prospects and added AI-centric uses still make it a reasonable buy in my view. Should you invest $1,000 in Amazon right now? Before you buy stock in Amazon, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Adam Spatacco has positions in Alphabet and Amazon. The Motley Fool has positions in and recommends Alphabet, Amazon, and Berkshire Hathaway. The Motley Fool has a disclosure policy.
Toronto Star
an hour ago
- Toronto Star
Military parade set to kick off in nation's capital as protesters around the country decry Trump
WASHINGTON (AP) — Tanks, troops and marching bands assembled in the nation's capital Saturday for a massive parade of American military power requested by President Donald Trump, a show that was met by thousands of Americans around the country displaying another kind of power: protest. Hours before the parade honoring the Army's 250th anniversary was set to start, demonstrators turned out in streets and parks around the nation to decry the Republican president as a dictator or would-be king. They criticized Trump for using the military to respond to those protesting his deportation efforts and for sending tanks, thousands of marching troops and military aircraft out for a show in the U.S. capital.
